Subscribe or Manage Preferences
By Phoebe Starr An automated cell phone system used to monitor pa­tients with early rheumatoid arthri­tis (RA) is a potential way to extend limited healthcare resources.
By Rosemary Frei, MSc Washington, DC—Only one fifth of Medicaid patients with rheumatoid arthritis (RA) are adherent to their med­i­­cation regimen, according to an analysis from the University Of Mississip­pi of a Mississippi Medicaid database that was presented at the 2012 International Society for Pharmacoeconomics and Outcomes Research meeting.
San Francisco, CA—There is no way around the fact that American-style capitalism is at the root of drug development, and the costs associated with that endeavor, according to Alex W. Bastian, MBA, Vice President of Market Access, GfK Bridgehead, San Francisco, CA. GfK provides consulting services to pharmaceutical, biotechnology, medical device, and diagnostics industries.
By Alice Goodman Madrid, Spain—Abatacept (Orencia) and adalimumab (Humira) were similarly cost-effective for the treatment of adults with rheumatoid arthritis (RA) who had an inadequate response to methotrexate, according to a cost-effectiveness subanalysis of the AMPLE (Abatacept Versus Adalimumab Com­parison in Biologic Naive RA Subjects with Background Methotrexate) trial.

Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.

“At 12 and 18 months after azacitidine treatment, there were 26% and 38% reductions in RBC transfusion costs, respectively, per patient compared with the 6 months before therapy,” said Eric Tseng, MD, Department of Hematology, University of Toronto, Ontario, Canada.

Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.

“At 12 and 18 months after azacitidine treatment, there were 26% and 38% reductions in RBC transfusion costs, respectively, per patient compared with the 6 months before therapy,” said Eric Tseng, MD, Department of Hematology, University of Toronto, Ontario, Canada.

Pharmacy cost now the key driver of RA expenditures By David Hawk The total incremental costs for the treatment of patients with rheumatoid arthritis (RA) in the United States accounted for $22.3 billion in 2008, according to a new cost analysis.
By Wayne Kuznar San Diego, CA—Biologic response modifiers for the treatment of patients with rheumatoid arthritis (RA) do not appear to offset healthcare costs over 3 years, according to an econometric analysis presented at the 2013 American College of Rheumatology meeting. The finding comes from a population-based cohort of more than 700 patients with RA in British Columbia, Canada, identified from an administrative database.
Greatest number of years lived with disability By Eileen Koutnik-Fotopoulos Although life expectancy in the United States increased during the period of 1990 to 2010, and the United States spends more per person on health than any other country, Americans are not necessarily healthy. And even though life expectancy has risen over the years in the United States, the increase is lower than that in other developed countries. Morbidity and chronic disability now account for nearly 50% of the US health burden.
By Rosemary Frei, MSc A study based on a real-world cost utility of 5 tumor necrosis factor (TNF)-alpha inhibitors used for the treatment of moderate-to-severe rheumatoid arthri­tis (RA) suggests that etanercept (Enbrel) plus methotrexate (MTX) is the most cost-effective approach for this patient population from a health plan perspective, based on a payer willingness-to-pay threshold of $139,143 (ie, 3 times the average US gross domestic product per capita) per quality-adjusted life-year (QALY) gained from a treatment.
Page 1 of 8
Results 1 - 10 of 75
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology